Read our groundbreaking publication establishing the first AI benchmark in automated disease classification in Hidradenitis suppurativa (HS) patients by using Scarletred®Vision und calibrated clinical images.

EU Startup News covers innovative startups and emerging trends in the tech industry and talks about SCARLETRED providing standardization and objective skin analysis as a pioneering digital health scaleup.

The 7th Dermatology Drug Development Summit in Boston, USA, for inflammatory skin diseases presents novel therapeutics for rare and common skin diseases such as Atopic Dermatitis, Hidradenitis suppurativa, and more.

Our CEO Harald Schnidar is invited to present the results of a cooperation with GALDERMA and the University of Tübingen, wherein Scarletred®Vision confirmed the therapeutic efficacy of Ivermectin in Rosacea patients.

Discover our newest publication about Ivermectin treatment in rosacea patients in cooperation with the university clinic Tübingen, Germany, and how Scarletred®Vision helped monitor signs and symptoms. 

Die Seestadt Apotheke in 1220, Wien, lädt zu ihrem kosmetischen Beratungstag am 29.11.2022 ein. Unterstützt durch Produkte von Eucerin, wird Scarletred exklusiv helfen den Hautzustand zu erfassen und analysieren.

Following a successful launch in Europe in 2019, and a tremendous online experience in 2021, the 3rd Dermatology Drug Development Europe Summit, returns in April 2022 in Frankfurt, Germany.

SCARLETRED is currently featured at the Arab Health 2022 exhibition in Dubai, among other companies in medical and healthcare-related categories. The networking event helps to connect and support innovations in healthcare.

The business magazine Gewinn discusses how Scarletred®Vision is an excellent addition to the safety and monitoring of injection site reactions (ISRs) in vaccine development.

The 5th Annual Dermatology Drug Development Summit focusing on development and innovation of therapies and research targeting inflammatory skin diseases, returns to Boston for 2021.

The Inflammatory Skin Disease Summit is a jointly organized event by the Icahn School of Medicine at Mount Sinai and the Austrian Academy of Sciences.

The clinically validated and award-winning technology, Scarletred®Vision, is on market since 2015, enabling high quality remote skin imaging and objective analysis in over 3000 cutaneous disorders.

​​In the round table discussion of the leading financial domain Börse Express, Marinomed, Scarletred, PHH Rechtsanwälte, and EOSS Industries discussed the development and hurdles of Austrian life science start-ups.

With patient safety in mind, SCARLETRED®Vision can be used as a digital aid to measure and document treatment safety and efficacy of newly developed JAK inhibitors either on site and/or home based clinical trials.

Hidradenitis suppurativa (HS) is an autoinflammatory skin condition that causes abscesses and scarring on the skin and affects about 1-4% of the total population (Ballard & Schuman, 2020). 

People suffering from atopic dermatitis struggle with the condition itself and stigmatization, making digital analysis of disease and treatment vital to clinical management to enhance their quality of life using SCARLETRED.

SCARLETRED’s certified medical device provides medical professionals with a novel digital solution to allow them to assess and analyze the individuals’ affected areas in an accurate, time-efficient, and user-friendly manner.

Discover our newest publication about Ivermectin treatment in rosacea patients in cooperation with the university clinic Tübingen, Germany, and how Scarletred®Vision helped monitor signs and symptoms. 

The traditional assessment of skin texture based on multiple health professionals can lead to inconsistent results making standardized digital dermatological monitoring, as provided by SCARLETRED, an essential tool.

Psoriasis is a chronic inflammatory disease of the skin associated with red, raised plaques and scaly skin. Psoriasis is a global problem affecting approximately 2-3% of the total population.

Patient-reported outcome (PRO) refers to a health outcome directly based on patient self-reporting. While some measures can be captured during site visits, others may be tracked more efficiently close to real-time.

SCARLETRED’s mobile technology, Scarletred®Vision, provides clinically validated R&D tools to document, analyse, and monitor skin color and pigmentation variations in multi-centric or home based cosmetics studies.

Onychomycosis is an infection of the nail caused by fungal organisms. With SCARLETRED’s digital technology, experts can quantify and monitor disease progression allowing for consistent and personalized treatment.

Being a chronic inflammatory skin disorder, patients with rosacea need standardized tools, as provided by SCARLETRED, to improve the condition’s analysis and treatment and overcome psychosocial stigmatization.

Standardized documentation and scoring of injection site reactions is a crucial part of clinical trials, as local development of skin erythema can reflect on the effectiveness and side effects of an investigational product.

Skin cancer is one of the most common types of cancer but also the most preventable one. The incidence rates for non-melanoma skin cancer drastically increased, and currently, there are 2-3 million cases each year.

Solar lentigo, also called age spots, is a common form of hyperpigmentation, especially in adults older than 50, caused by natural or artificial ultraviolet light exposure.

Vitiligo is a long-term pigmentation disorder affecting 0.5 - 1% of individual. SCARLETRED is revolutionizing dermatology by allowing the standardization of the assessment and monitoring of vitiligo.

The skin is the primary interface between nurse and patient. With SCARLETRED, pigmentation disorders can be objectively monitored, improving dermatological and cosmetic dermatological services.

Chronic wound is a medical condition, affecting up to 4% of all people worldwide. The wound care market is one of the biggest in the healthcare system globally, standing now at approx. USD 10.4 billion.

Non-healing wounds pose a significant challenge in clinical medicine and present severe difficulties to millions of patients worldwide. The management of chronic wounds remains a challenging task in terms of their assessment.

Due to the COVID-19 pandemic, researchers need to adjust clinical trial setups due to the stay-at-home orders and risk of virus transmission. The golden time of virtual and home-based clinical trials has started.

The current COVID-19 pandemics forced many clinical trials to grind to a halt, stalling research until restrictions are lifted. Scarletred offers a solution for the documentation and monitoring of changes on the skin surface.